Compugen Ltd. Third Quarter Financial Statements To Be Released November 7, 2016
HOLON, Israel, October 10, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will issue its quarterly financial statements for the third quarter 2016 on Monday, November 7. The Company also announced today that it will host its third quarter conference call the following week, on Wednesday, November 16, 2016 at 10:00 am ET.
On Friday, October 7, 2016, the Company announced that John Hunter, Ph.D., Site Head and Vice President, Antibody R&D, Compugen USA, Inc., will present data on the Company's CGEN-15029 novel immune checkpoint program on Friday, November 11 at 11:45 am ET, at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The Company also plans to issue a separate press release with respect to such data.
The third quarter conference call is being postponed to the week following the release of the financial statements in order to include discussion of the CGEN-15029 data during the call. Information regarding accessing this quarterly call will be provided in advance of the call.
About Compugen
Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties, and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.